Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13448493 | 0.83 | PTGS2 (0.72) | PTGS2TDO2 | |
| SCHEMBL13031001 | 0.83 | KCNH2 (0.44) | PTGS2TDO2 | |
| SCHEMBL15771506 | 0.80 | ALDH1A1 (0.51) | PTGS2 | |
| SCHEMBL22636673 | 0.80 | PTGS2 (0.49) | PTGS2 | |
| SCHEMBL29430848 | 0.80 | PTGS2 (0.49) | PTGS2 | |
| SCHEMBL3793523 | 0.78 | TAAR1 (0.52) | PTGS2TDO2 | |
| SCHEMBL4214071 | 0.78 | PTGS2 (0.69) | PTGS2 | |
| SCHEMBL6724238 | 0.77 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL27422657 | 0.77 | PTGS2 (0.38) | PTGS2TDO2 | |
| SCHEMBL15771508 | 0.77 | ALDH1A1 (0.47) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117309-B1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-2117309-B1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8377954-B2 | Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | Merck, Sharp & Dohme, Corp (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377954-B2 | Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | Merck, Sharp & Dohme, Corp (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377954-B2 | Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | Merck, Sharp & Dohme, Corp (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100076004-A1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-25 | — | — | US | disclosed |
| US-20100076004-A1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-25 | — | — | US | disclosed |
| US-20100076004-A1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-25 | — | — | US | disclosed |
| EP-2117309-A1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008085509-A1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008085509-A1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076004-A1 | BICYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | PTGS2 1377/4885TDO2 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.